Allergan Expands Leading Research and Development NASH Program with Novartis Clinical Collaboration
Collaboration Focused on Phase 2b Clinical Trial to Evaluate Use of Allergan's Cenicriviroc (CVC) and Novartis Lead FXR Agonist to Treat NASH
NASH Fastest Growing Cause of Liver Cancer and Liver Transplant in the U.S.
DUBLIN, April 18, 2017 -- (Healt... Biopharmaceuticals Allergan, Novartis, cenicriviroc, non-alcoholic steatohepatitis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Alcoholism | Allergy | Cancer | Cancer & Oncology | Clinical Trials | Liver | Liver Transplant | Pharmaceuticals | Transplant Surgery | Transplants | Urology & Nephrology